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Summary
Background: PLC-b signaling is generally thought to be medi-
ated by allosteric activation by G proteins and Ca2+. Although
availability of the phosphatidylinositol-4,5-biphosphate (PIP2)
substrate is limiting in some cases, its production has not
been shown to be independently regulated as a signaling
mechanism. WNK1 protein kinase is known to regulate ion
homeostasis and cause hypertension when expression is
increased by gene mutations. However, its signaling functions
remain largely elusive.
Results: Using diacylglycerol-stimulated TRPC6 and inositol
trisphosphate-mediated Ca2+ transients as cellular biosen-
sors, we show that WNK1 stimulates PLC-b signaling in cells
by promoting the synthesis of PIP2 via stimulation of phospha-
tidylinositol 4-kinase IIIa. WNK1 kinase activity is not required.
Stimulation of PLC-b by WNK1 and by Gaq are synergistic;
WNK1 activity is essential for regulation of PLC-b signaling
byGq-coupled receptors, and basal input fromGq is necessary
for WNK1 signaling via PLC-b. WNK1 further amplifies PLC-b
signaling when it is phosphorylated by Akt kinase in response
to insulin-like growth factor.
Conclusions:WNK1 is a novel regulator of PLC-b that acts by
controlling substrate availability. WNK1 thereby coordinates
signaling between G protein and Akt kinase pathways.
Because PIP2 is itself a signaling molecule, regulation of PIP2
synthesis byWNK1 also allows the cell to initiate PLC signaling
while independently controlling the effects of PIP2 on other
targets. These findings describe a new signaling pathway for
Akt-activating growth factors, a mechanism for G protein-
growth factor crosstalk, and ameans to independently control
PLC signaling and PIP2 availability.Introduction
Mammalian WNK kinases are a family of four serine-threonine
protein kinases with an atypical kinase active site [1–3]. Muta-
tions in WNK1 and WNK4 cause the autosomal-dominant
disease pseudohypoaldosteronism type 2 (PHA2), which is
characterized by hypertension and hyperkalemia [2]. WNKs
regulate various ion transporters through both kinase
activity-dependent and -independent mechanisms [3, 4]. For4These authors contributed equally to this work
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huang@utsouthwestern.edu (C.-L.H.)example, WNK1 and WNK4 phosphorylate and activate
Ste20-related proline-alanine-rich kinase (SPAK) and oxidative
stress-responsive kinase-1 (OSR1), which in turn activate
cation-chloride cotransporters NCC and NKCC [5–7]. Through
kinase-independent events, WNK1 binds and somehow
activates SGK kinase, causing it to activate the epithelial Na+
channel ENaC [8]; and WNK1 and WNK4 interact with the
endocytic scaffold protein intersectin to enhance endocytosis
of the renal K+ channel ROMK [9]. Dysregulation of ion trans-
port in the kidney contributes to the hypertension and hyper-
kalemia of PHA2.
The functions of WNKs extend beyond regulation of ion
homeostasis. WNK1 is ubiquitously expressed, and homozy-
gous gene inactivation in mice causes cardiovascular devel-
opmental arrest and embryonic death [10]. WNK1 activates
ERK5, and knockdown of WNK1 decreases activation of
ERK5 by epidermal growth factor receptors [11]. WNK2 binds
the small GTPases RhoA and Rac1. WNK2 knockdown
decreases RhoA activation but promotes Rac1 activation
[12]. The Gq-coupled angiotensin II receptor regulates the
activity of the NCC cotransporter through the WNK4 signaling
pathway [13], indicating functional interactions between WNK
and G protein signaling pathways.
Upstream regulation of the WNKs is incompletely under-
stood, and it is likely that several distinct mechanisms of
WNK activation are used in different cells [3, 4]. WNK1 is a
substrate of Akt kinase [14, 15], which is a target of phospha-
tidylinositol 3-kinase (PI3K)-activating growth factors such as
insulin and insulin-like growth factors (IGFs). Insulin and IGFs
activate PI3K and its phosphatidylinositol-1,4,5-triphosphate
(PIP3) product recruits and activates Akt to phosphorylate
WNK1 at threonine-58. It has been reported that Akt-catalyzed
phosphorylation of WNK1 at T58 alters the ability of WNK1 to
regulate membrane trafficking of ENaC and ROMK channels
[8, 16].
Phospholipase C-bs (PLC-bs) are important effectors of
G protein-coupled receptor (GPCR)-mediated signaling path-
ways [17, 18]. They hydrolyze phosphatidylinositol-4,5-
biphosphate (PIP2), itself a signaling molecule, to form two
other second messengers, diacylglycerol (DAG) and inositol-
1,4,5-trisphosphate (IP3). PLC-bs are stimulated by Ga
subunits of the Gq family, by Gbg subunits of the Gis, and, in
the case of PLC-b2, by Rac [17–19]. The concentration of
PIP2 in the plasma membrane is limiting for PLC-b activity,
and resynthesis of the substrate initiated by phosphatidylino-
sitol-4-kinase (PI4K) after depletion is important for sustained
PLC-b signaling [20, 21]. This dependence on substrate
concentration agrees with in vitro studies showing that PLC
activity increases linearly with the concentration of PIP2
regardless of stimulation by G proteins or Ca2+ [22, 23].
However, it is not knownwhether PIP2 production can be inde-
pendently regulated as a signaling mechanism and, if so, by
what physiological stimulus.
We show here that WNK1 stimulates PLC-b signaling by
promoting the synthesis of PIP2 via stimulation of PI4KIIIa.
Stimulation of PLC-b by WNK1 and by Gaq-GTP is thus
synergistic, and WNK1 activity is essential for regulation of
PLC-b signaling by Gq-coupled receptors. Phosphorylation
Figure 1. Activation of TRPC6 by WNK1 Requires PLC Activity and Is
Independent of WNK1 Kinase Activity
(A) Top shows domain structure of rat WNK1. Bottom shows whole-cell
patch-clamp recording of TRPC6. Intracellular free [Ca2+] was 70 nM except
as indicated in (F). The following abbreviations are used: Akt, site of phos-
phorylation by Akt; PRD, proline-rich domain; KD, kinase domain; CCh:
carbachol (100 mM); M3R: M3 muscarinic cholinergic receptor.
(B) Activation of TRPC6 by CCh via M3R, GTPgS, or WNK11–491. HEK cells
were transfected with TRPC6 with or without M3R. Data points (circles
and error bars) are means 6 SEM of inward current density (pA/pF
at 2100 mV; n = 5 for each). At the end of each recording, extracellular
Na+ was replaced by the TRPC6-impermeable cation N-methyl-D-gluc-
amine (NMDG) to gauge the background current. Inset shows current-
voltage (I-V) relationships of activated TRPC6 currents.
(C) Concentration-response curve for activation of TRPC6 by WNK11–491.
(D) Effect of PLC inhibitor U73122 or inactive analog U73343 (2.5 mM each)
on WNK11–491 activation of TRPC6. Inward current is at 2100 mV from
a representative experiment. Similar results were observed in six indepen-
dent experiments.
(E) Cells were preincubated with 15 mM edelfosine for 1 hr and washed
before recording. TRPC6 currents in response to 100 nM WNK11–491, 5 nM
PLC-b1, or both were measured.
(F) TRPC6 currents in response to WNK11–491 under 0 or 70 nM intracellular
calcium. 1-oleoyl-2-acetyl glycerol (OAG) was applied as indicated.
(G) TRPC6 currents were measured in cells with or without intracellular
application of 3 nM WNK11–491. OAG was applied to the extracellular
solution at indicated concentrations. Although this concentration of
WNK11–491 by itself does not activate TRPC6, it potentiated M3R activation
of the channel (see Figure 3B; Figure S1).
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1980of WNK1 by the PI3K-Akt kinase cascade enhances the ability
of WNK1 to synergistically regulate PLC-b signaling via
synthesis of PIP2. Regulated control of substrate availability
represents a novel mechanism for regulation of PLC-b activity
and for crosstalk between Gq-coupled receptors and recep-
tors that activate the Akt kinase pathway.
Results
WNK1 Activates TRPC6 Channels
The TRPC6 channel is directly activated by DAG, a product
of the PLC-catalyzed hydrolysis of PIP2 [24]. Inspired by a
serendipitous observation that WNK1 knockdown altered Gq
signaling, we used TRPC6 as a biosensor to examine the
role of WNK1 in PLC-b signaling in native cell membranes.
Full-length WNK1 is difficult to purify, and we tested the
effect of WNK1 on TRPC6 by intracellular application of a
purified fragment of rat WNK1 consisting of residues 1–491
(WNK11-491), which contains the Akt-phosphorylation site,
the protein kinase domain, and an N-terminal proline-rich
domain (Figure 1A). As shown for HEK293 cells in Figure 1B,
intracellular WNK11–491 increased TRPC6 current density,
peaking in these cells at around 1–2 min and lasting for
>5 min. The half-maximal concentration of WNK11–491 for
activation of TRPC6 was w50 nM (Figure 1C). WNK11–491
also activates TRPC6 in membranes of HeLa cells (see Fig-
ure 6) and mouse embryo fibroblasts (see Figures 2C and
2D). TRPC6 was also activated by GTPgS, consistent with
Gq-PLC-b signaling to produce DAG, and by the muscarinic
agonist carbachol in cells that express the Gq-coupled M3
muscarinic cholinergic receptor (Figure 1B).
Application of WNK11–491 to the cytoplasmic face of de-
tached plasma membranes also activated TRPC6 single
channel activity in membranes of cells that express TRPC6
(see Figure S1A available online) but not in membranes from
control cells. Thus, the cellular components required for acti-
vation of TRPC6 by WNK1 are contained in or are bound to
the excised plasma membrane patch. Stimulation of TRPC6
was selectively blocked by antibody against amino acid resi-
dues 160–176 of WNK1 (Figure S1B). Purified WNK11–491
carrying a kinase-dead K233M mutation [1, 9] retained full
ability to activate TRPC6 (Figure S1C), indicating that kinase
activity of WNK1 is dispensable.
Activation of TRPC6 by WNK1 Requires PLC Activity
Several experimental results argue that the activation of
TRPC6 by WNK1 is mediated by PLC-b-catalyzed production
of the known TRPC6 activator DAG. First, activation of
TRPC6 by WNK11–491 was blocked by the PLC inhibitors
U73122 (Figure 1D) and edelfosine [25] (Figure 1E). Application
of 1-oleoyl-2-acetyl glycerol (OAG), a soluble and membrane-
permeant DAG, restored TRPC6 activity in the continued
presence of U73122, which excludes effects of U73122 on
the channel itself or on other components upstream of PLC.
Second, because edelfosine acts slowly [25], we could rescue
WNK1 signaling by addition of purified PLC-b1 after endoge-
nous PLC was inhibited (Figure 1E). After edelfosine pretreat-
ment, application of both purified PLC-b1 and WNK11–491
caused robust activation of TRPC6. Application of PLC-b1
without WNK1 had no effect, indicating that both WNK1 and
PLC-b1 are required for activation of TRPC6. Third, PLC
activity is dependent on cytosolic Ca2+ [17, 18], and removal
of Ca2+ blocked TRPC6 stimulation by WNK11–491, but not
direct stimulation by OAG (Figure 1F). Based only on thedata above, WNK11–491 might activate TRPC6 by protecting
DAG from hydrolysis by DAG lipase or phosphorylation by
DAG kinase. However WNK11–491 did not alter the potency
with which OAG activates TRPC6 (Figure 1G), indicating that
its effect is at the level of PLC. Together, these results provide
compelling evidence that WNK1 activates TRPC6 by stimula-
tion of PLC to produce DAG, the proximal activator.
We alsomeasured intracellular Ca2+ release triggered by IP3,
another product of PIP2 hydrolysis, as a readout for WNK1’s
effects on PLC activity. Microinjection of anti-WNK1 antibody
or knocking down endogenous WNK1 by small interfering
Figure 2. Role of Gq in the Activation of TRPC6 byWNK1
(A) GDPbS (0.2 mM) inhibits WNK1 activation of TRPC6.
(B) Anti-WNK1 antibody inhibits TRPC6 activated by
GTPgS. TRPC6 single channel activity was recorded
from inside-out patches from TRPC6-expressing HEK
cells. Buffer, GTPgS, anti-WNK1 Ab and/or OAG was
applied to the cytoplasmic face as indicated. Each data
point is NPo (number x open probability) averaged over
30 s. Inset shows mean6 SEM of peak open probability.
*p < 0.01 versus buffer, and **p < 0.01 GTPgS versus
GTPgS+anti-WNK1 antibody.
(C) Whole-cell WNK1-activated TRPC6 currents were
measured in Gaq/11 null fibroblasts transfected with
wild-type Gaq (Gaq/WT) or empty vector.
(D) Single channel activity was measured in inside-out
patches from TRPC6-expressing Gaq/11 null fibroblasts
that have endogenous WNK1 depleted by small inter-
fering (siRNA). Data show responses to GTPgS-preacti-
vated Gaq (Gaq*) and/or WNK1 applied to the cyto-
plasmic face. Holding membrane potential is 280 mV.
Inset shows mean 6 SEM of peak open probability.
*p < 0.01 versus buffer, **p < 0.05 versus buffer, and
***p < 0.02 between indicated groups.
(E and F) Single channel activity was recorded in inside-
out patches from HEK cells expressing both TRPC6 and
wild-type Gaq (Gaq/WT) (E) or G188S mutant Gaq (Gaq/
G188S) (F). Buffer, WNK11–491, and/or RGS4 (0.5 mM)
was applied to the cytoplasmic face as indicated. NPo
values were averaged every 20 s. There was a 2 min
time gap between application of buffer and WNK1 (see
also Figure S2).
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1981RNA (siRNA) reduced the intracellular Ca2+ increases in re-
sponse to carbachol (Figures S1D–S1F). Endogenous WNK1
is thus required for normal PLC-b signaling in response to
stimulation of Gq.
WNK1 Works in Parallel with Gq to Synergistically
Stimulate TRPC6
The PLC-bs are activated by Gaq [17, 18]. GDPbS, which
blocks G protein activation, inhibited the stimulation of
TRPC6 by WNK11–491 (Figure 2A). GTPgS stimulated the
TRPC6 current without added WNK1, and stimulation was
blocked by anti-WNK1 antibody (Figure 2B; Figures S2A
and S2B). These data suggest both that some G protein
is required for WNK1 stimulation of TRPC6 and that en-
dogenous WNK1 is required for TRPC6 stimulation by a Gprotein. To determine whether WNK1 requires
activation of PLC-b by Gq/11 in cells, we mea-
sured TRPC6 regulation by WNK1 in murine
Gaq
2/2-Ga11
2/2 embryonic fibroblasts [26].
In intact Gaq/11 null cells, WNK11–491 failed to
activate TRPC6, and expression of wild-typeGaq restored activation by WNK1 (Figure 2C). When the con-
stitutively active Q209L-Gaq mutant was expressed, addition
of WNK11–491 further activated TRPC6 (Figures S2C and
S2D), which argues that WNK1 and Gaq act in parallel rather
than in series to stimulate DAG synthesis by PLC-b.
When WNK1 was depleted in the Gaq/11 null cells by siRNA,
neither WNK11–491 nor Gaq-GTPgS alone stimulated TRPC6
substantially, only simultaneous addition of both activators
produced major TRPC6 opening (Figure 2D). Moreover, the
Gq inhibitor RGS4 blocked activation of TRPC6 by WNK1 in
cells and the N128Gmutant of RGS4 [27] had no effect (Figures
S2E and S2F). In detached patches, inhibition by RGS4 was
reduced and delayed by expression of the RGS-insensitive
G188S mutant of Gaq [28, 29] (Figures 2E and 2F). Thus,
WNK1 and activated Gaq stimulate TRPC6 synergistically.Figure 3. Role of WNK1 in Activation of TRPC6 by Gq-
Coupled Receptor
(A) Whole-cell inward TRPC6 current density in response
to CCh with anti-WNK1 Ab, GDPbS, or control buffer
applied via patch pipettes. *p < 0.01 for WNK1-Ab versus
control.
(B) Whole-cell CCh-induced TRPC6 currents were re-
corded in the presence of control buffer or WNK11–491
(3 nM), a concentration that does not appreciably stimu-
late TRPC6 by itself. *p < 0.01 for WNK1 versus buffer
(see also Figure S3).
Figure 4. Role of PI4K in the Activation of TRPC6 by WNK1
(A) Effect of wortmannin (Wmn) on whole-cell TRPC6 currents activated by
WNK11–491. Cells were pretreated with 10 mM wortmannin or vehicle
(dimethyl sulfoxide [DMSO]) for 10min before recording. *p < 0.01 for vehicle
versus wortmannin.
(B) Whole-cell TRPC6 currents in response to WNK11–491 coapplied with
monoclonal anti-PI4P antibody or control mouse IgM. *p < 0.01 for control
IgM versus PI(4)P-Ab.
(C) Whole-cell TRPC6 current in response to intracellular delivery of 100 nM
PI4KIIIbpreincubatedwith orwithout 10 mMwortmannin for 10min. *p < 0.01
for vehicle versus wortmannin. Note that both type IIIa and IIIb PI4K can
generate PI4P for synthesis of phosphatidylinositol 4,5-biphosphate (PIP2)
in the membrane. Due to difficulties in purification of PI4KIIIa, we used
only PI4KIIIb for experiments here. In all panels, data point is mean 6 SEM
of inward current density, n = 5–9 for each condition (see also Figure S4).
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1982WNK1 Activity Is Necessary for Activation of TRPC6
by Gq-Coupled Receptors
Intracellular application of anti-WNK1 antibody markedly
blunted the activation of TRPC6 by agonist through the
expressed M3 muscarinic receptor (Figure 3A), the a1A-, a1B-
adrenergic receptors, and H1 histaminergic receptor in HEK
cells (Figures S3A–S3C) or through endogenous muscarinic
receptor in HeLa cells (Figure S3D). Conversely, increased
WNK1 activity potentiated activation of TRPC6 by M3 re-
ceptor. Intracellular application of 3 nM WNK11–491, which istoo low to activate TRPC6 by itself, approximately doubled
the TRPC6 current elicited by M3 muscarinic stimulation (Fig-
ure 3B). Thus, some level of endogenous WNK1 activity is
necessary for full Gq-PLC-b signaling and additional WNK1
potentiates Gq signaling in cells.
Anti-WNK1 antibody did not significantly inhibit activation
of TRPC6 by the Gi-coupled M2 muscarinic receptor (Fig-
ure S3E). However, Gi is a less effective activator of PLC-bs
[17, 18], and TRPC6 activation by the M2 receptor is much
smaller than that by the Gq-coupled receptors (Figure S3E
versus Figure 3A). This apparent selectivity of anti-WNK1 anti-
body for Gq-coupled receptors suggests that WNK1 is needed
to support the higher flux of the Gq-PLC-b pathway but is not
detectably required for Gi-PLC-b signaling.
Although these data are consistent with the stimulation of
PLC-b activity by WNK1, we did not find any effect of purified
WNK11–491 on the activity of purified PLC-b1, 2, or 3; its regu-
lation by Gaq or Gbg; or regulation of Gq by M1 muscarinic
receptors (Figure S4).
Activation of TRPC6 by WNK1 via PI4K-Mediated PIP2
Synthesis
The interdependence and mutual potentiation of TRPC6 acti-
vation by the Gaq and WNK1 pathways suggests that they
each increase the activity of PLC-b by distinct mechanisms.
Gaq allosterically stimulates the catalytic activity of PLC-b.
We therefore asked whether WNK1 acts by increasing the
concentration of the PIP2 substrate. Generation of phosphati-
dylinositol 4-P (PI4P) by PI4K is believed to be the first step
in the synthesis of PIP2 [30]. Pretreatment of cells with the
PI4K inhibitor wortmannin inhibited activation of TRPC6 by
WNK11–491 (Figure 4A) as did simultaneous application of
an anti-PI4P antibody [31] (Figure 4B). Last, intracellular appli-
cation of PI4KIIIb activated TRPC6 even in the absence of
added WNK1, and pretreatment with wortmannin prevented
activation (Figure 4C). PI4P synthesis is thus involved in the
stimulation of TRPC6 by WNK1, and WNK1 can be mimicked
by addition of a PI4K.
We used the GFP-tagged pleckstrin homology (PH) domain
of PLC-d1 and confocal imaging to examine the role of WNK1
in the degradation and resynthesis of PIP2 in the plasma
membrane. The PLC-d1-PH domain binds both PIP2 and IP3
with relatively high affinity and specificity [32–34]. In cells
that express M3 receptor, addition of carbachol decreased
GFP-PLC-d1-PH fluorescence at the plasma membrane,
indicating reduced PIP2 and increased fluorescence in the
cytosol, indicating increased IP3 (Figure 5). Both effects
peak w45 s after carbachol addition and then decline to
prestimulus levels, reflecting PLC-b-catalyzed hydrolysis of
PIP2 and its subsequent resynthesis.
Microinjection of anti-WNK1 antibody both delayed and
decreased the recovery of GFP-PLC-d1-PH fluorescence at
the plasma membrane after treatment with carbachol.
Instead of the monophasic return to baseline in <3 min ob-
served in control cells, cells treated with anti-WNK1 antibody
displayed biphasic recovery of plasma membrane fluores-
cence that was onlyw50% complete after 15 min. The return
of cytosolic fluorescence to baseline was also biphasic, with
a greatly prolonged and incomplete second phase. These
data indicate that anti-WNK1 antibody substantially inhibits
resynthesis of PIP2 after a burst of PLC activity. Taken
together with the effects of the anti-PI4P antibody, they
indicate that WNK1 is necessary to maintain cellular PIP2
synthesis.
Figure 5. Anti-WNK1 Antibody Delays and Inhibits
Plasma Membrane PIP2 Resynthesis Following
Receptor-Stimulated Hydrolysis
HeLa cells transfected with M3R and GFP-tagged PLC-
d1-pleckstrin homology domain were microinjected
with control IgG or anti-WNK1 antibody and stimulated
by 1 mM CCh.
(A) Changes in fluorescence intensity at the plasma
membrane (decrease) and cytosol (increase) in response
to carbachol were normalized by setting maximal
change to 1.0. Data are means 6 SEM of 18 and 20 cells
(seven separate experiments) that were microinjected
with control rabbit IgG or anti-WNK1 antibody, respec-
tively.
(B) Ratio of fluorescence intensity in the plasma
membrane to that in cytosol from (A). Lines indicate
slopes of the initial recovery rates (0.032 6 0.002 and
0.014 6 0.002 for control IgG and anti-WNK1 antibody,
respectively; p < 0.01).
(C) Representative confocal images (obtained across the
middle of cells) from one of seven experiments showing
fluorescence at the plasma membrane and cytosol
before addition of CCh and at 45 s (peak), 90 s, and
180 s after addition of CCh. Signal intensity is shown
by pseudocolor.
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The PI4KIIIa isozyme is believed to be primarily responsible
for resynthesis of PIP2 in the plasma membrane during
receptor stimulation of PLC [30]. To determine whether
WNK1 regulates PI4KIIIa, we studied effects of manipulating
WNK1 activity in cells that express recombinant PI4KIIIa,
where this isoform is the predominant PI4K activity (w95%)
in a light membrane fraction, which includes plasma mem-
branes (Figure 6A). Knockdown of WNK1 by siRNA decreased
both PI4K activity and the amount of immunoreactive PI4KIIIa
in the light membrane fraction by 35%–40% (Figures 6B–6E)
and increased the abundance of PI4KIIIa in cytosol (Figures
6D and 6E). WNK1 knockdown did not alter the amount of
PI4KIIIa in the total postnuclear supernatant (PNS). These
data suggest that WNK1 recruits PI4KIIIa from cytosol to the
light membrane fraction, presumably the plasma membrane.
Recruitment may be indirect, because we did not detect phys-
ical association between PI4KIIIa and purified WNK11–491 in
pull-down assays.
WNK1 failed to activate TRPC6 in PI4KIIIa-knockdown cells
(Figures 6F and 6G) and expression of PI4KIIIa in the knock-
down cells rescued activation by WNK1. These results are
consistent with the idea that WNK1 increases PIP2 synthesis
by recruitment of PI4KIIIa to its site of action and that the
consequently increased availability of PIP2 synergistically
enhances Gq-coupled receptor signaling through PLC-b.
IGF1 Potentiates Gq-PLC-b Signaling via PI3K
and Akt-Mediated Phosphorylation of WNK1
The physiological role of WNK1 in the regulation of Gq-PLC-b
signaling was further supported by the finding that IGF1,
a known upstream activator of WNK1, enhances the effect of
WNK1. Pretreatment with IGF1 in serum-starved cells potenti-
ated the activation of TRPC6 by either carbachol (Figures 7A
and 7B) or GTPgS (Figures S5A and S5B), although IGF1 did
not alter basal TRPC6 current. Lack of effect on the basal
current is probably due to a low basal output from Gq-PLC-b
in serum-starved cells, and IGF1 activated TRPC6 in these
cells when prestimulated by GTPgS (Figure S5C). IGF1 alsoenhanced carbachol-induced intracellular Ca2+ transients
(Figure S5D), consistent with a final common site of action at
PLC-b. IGF1 did not increase the cell-surface abundance of
TRPC6 (Figure S5E).
Several observations argue that IGF1 potentiates GPCR-Gq
signaling through a PI3K-Akt-WNK1-PI4KIIIa sequence. First,
wortmannin, at a low concentration selective for PI3K
(20 nM), blocked the effect of IGF1 on Gq signaling. Knock-
down of WNK1 also blocked the ability of IGF1 to potentiate
carbachol’s effect (Figure 7C). Expression of wild-type
WNK1, but not the T58A mutant WNK1, restored the ability
of IGF1 to enhance carbachol activation of TRPC6 in WNK1-
knockdown cells (Figure 7D), indicating that the synergistic
effect of IGF1 and M3 muscarinic stimulation depends on
Akt-mediated phosphorylation of WNK1 at T58. Note that
both wild-typeWNK1 and the T58Amutant can support carba-
chol activation of TRPC6 in WNK1-knockdown cells. Thus,
T58-phosphorylation is not required for WNK1 amplification
of Gq-PLC-b signaling, but is indispensable for its potentiation
by IGF1.
Knockdown of PI4KIIIa also prevented enhancement of
carbachol activation of TRPC6 and intracellular Ca2+ tran-
sients by IGF1 (Figure 7E; Figure S5F). These results argue
that PI3K-dependent activation of Akt by IGF1 leads to phos-
phorylation of WNK1 and enhances the ability of WNK1 to
synergistically regulate PLC-b signaling by promoting PIP2
synthesis.
Discussion
Our data establish three new and distinct but interrelated
signaling mechanisms: the mutual dependence and syner-
gistic interaction between the Gq-PLC-b and Akt-WNK1
signaling pathways, the regulation of PLC-b activity by modu-
lating the availability of its substrate, and the regulation of
PI4KIIIa byWNK1 to control the concentration of PIP2-derived
second messengers.
As summarized in Figure 7F, blocking WNK1 activity mark-
edly inhibits PLC-b signaling by Gq-coupled receptors and,
Figure 6. Role of WNK1 in the Production of PI4P by
Expressed PI4KIIIa
(A) Chromatogram showing PI4K activity in membranes
prepared from HeLa cells transfected with vector or
complementary DNA (cDNA) for PI4KIIIa. The following
abbreviation is used: Std, PI4P standard.
(B) Chromatogram showing PI4P production by
membrane-associated recombinant PI4KIIIa from cells
that were cotransfected with control oligonucleotide or
WNK1 siRNA. Relative knockdown of WNK1 is shown
in the western blot.
(C) Mean 6 SEM of PI4P production from five separate
experiments, each with triplicate samples, as shown in
(B). *p < 0.01 for control versus knockdown.
(D) Abundance of PI4KIIIa in the postnuclear supernatant
(PNS), cytosol, andmembrane fractions from control and
WNK1 siRNA-transfected HeLa cells. A western blot at
bottom shows relative WNK1 knockdown.
(E) Mean 6 SEM (five separate experiments) of PI4KIIIa
abundance in the postnuclear supernatant (PNS),
cytosol, and membrane fraction in control (blue) and
WNK1 knockdown cell (red), shown relative to the
control. *p < 0.05 between indicated data.
(F) Whole-cell TRPC6 currents stimulated by WNK11–491
in cells cotransfected with control oligonucleotide or
siRNA for human PI4KIIIa, with either empty vector or
plasmid that encodes rat PI4KIIIa.
(G) Peak WNK1-induced inward current density from (F).
*p < 0.01 between indicated data.
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1984conversely, inhibiting Gq blocks PLC-b signaling by WNK1.
Inhibition could be exerted by several approaches and at
several steps in each pathway, both in cells and in detached
membrane patches. In each case, replenishment of the in-
hibited or depleted species, or stimulation of a downstream
component, restored normal activities of both WNK1 and
Gq-PLC-b. Importantly, WNK1 can elicit PLC signals without
added GPCR agonist, and WNK1 synergistically amplifies
the stimulation of PLC-b by Gq.
In contrast to G proteins, WNK1 increases PLC-b activity by
increasing the supply of the PIP2 substrate. Because the
concentration of PIP2 in the plasma membrane is below Km
[22, 23], PLC-b displays first-order substrate kinetics and
increase in available PIP2 linearly amplifies PLC-b output.
Note that WNK1 only modulates Gq signaling via PLC-b. Other
outputs, such as stimulation of a rho guanine nucleotide
exchange factor [35], are not involved. WNK1 thus alters the
spectrum of Gq outputs as well as its amplitude.
WNK1 promotes synthesis of PIP2 by somehow activating
PI4KIIIa (Figure 6; Figure 7F). PI4KIIIa is important for the re-
synthesis of PIP2 following hydrolysis by receptor-stimulated
PLC [30], but how the activity of PI4KIIIa is regulated is
unknown. The amount of PI4KIIIa is decreased in membranes
from WNK1 knockdown cells, suggesting that regulation of
PI4KIIIa by WNK1 may involve its redistribution between
plasma membrane and intracellular pools. However, WNK1must do more than just recruit PI4KIIIa to the
plasma membrane because it remains neces-
sary for PLC-b signaling in detached patches.
We have no evidence that WNK1 either binds
or phosphorylates PI4KIIIa, and additional
factors may be involved.
Regardless, our results indicate that the
activity of PI4KIIIa is regulated and that its
regulation by WNK1 is critical for PLC-bsignaling by Gq-coupled receptors. The basal activity of
WNK1 provides adequate tonic stimulation of PI4KIIIa to
provide PIP2 for normal PLC-b signaling. However, additional
WNK1 markedly amplifies signaling by Gq-coupled receptor
even at a concentration that does not by itself activate
TRPC6 (Figure 3B). In addition, PI3K-activating growth factors
such as IGF1 activate WNK1 to further potentiate Gq-PLC-b
signaling, probably via Akt-mediated phosphorylation of
WNK1 at T58 (Figure 7). These results suggest that WNK1 is
an important physiological mediator of the Akt kinase
signaling pathway and coordinates Akt signaling with the
Gq-PLC-b signaling pathway.
This action of WNK1 represents the first known instance of
acute control of PIP2 availability as a mechanism of regulation
of cellular DAG and IP3 concentrations without concurrent
stimulation of the intrinsic activity of PLC. Application of
WNK1 alone stimulates the production of DAG measured
using the TRPC6 biosensor by an amount comparable to
that initiated by GTPgS (Figure 1B). Some low output of
PLC-b, evidently dependent on basal input from Gaq, is
adequate to support this WNK1 signaling. By promoting PIP2
synthesis, WNK1 can also acutely modulate the amplitude of
receptor-stimulated PLC-b signaling and/or its duration. Inhi-
bition of endogenous WNK1 by anti-WNK1 antibody blocks
both the DAG and IP3 limbs of PLC-b signaling stimulated by
multiple Gq-coupled receptors by R50% (Figure 3A; Figures
Figure 7. IGF1 Enhances Gq-Coupled Receptor Activa-
tion of TRPC6 via WNK1
(A) Cells coexpressing TRPC6 and M3R were serum-
starved for 18 hr and incubated for 10 min with 100 ng/ml
IGF1, 20 nM wortmannin, both, or neither before rup-
tured whole-cell recording. Carbachol was applied to
the bath where shown.
(B) Peak CCh-induced current density from (A). *p < 0.01
between indicated groups.
(C) Peak CCh-induced inward current density in cells
transfected with control oligonucleotides or WNK1
siRNA and with or without IGF1 pretreatment. *p < 0.01
between indicated groups, and #, p < 0.01 versus
cells transfected with control oligo and without IGF1
pretreatment.
(D) Peak CCh-induced inward current density in cells
transfected with WNK1 siRNA and cDNA for either
wild-type WNK1 or T58A mutant WNK1 and with or
without IGF1 pretreatment. *p < 0.01 between indicated
data.
(E) Peak CCh-activated TRPC6 currents in cells trans-
fected with control oligonucleotides or PI4KIIIa siRNA
andwith or without IGF1 pretreatment. *p < 0.01 between
indicated data.
(F) Interaction of WNK1, Gq-PLC-b, and PI4KIIIa
signaling pathways. Components of the pathways are
shown in black. Inhibitors are color-coded per their
biochemical sites of action and placed where their
inhibitory effects on cellular signaling were noted in the
experiments. Pathways are indicated by black arrows.
The experimental results indicate that the point at which
Gq and WNK1 interact is at the level of PLC activity
(marked by dark green box) (see also Figure S5).
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1985S1D–S1F; Figure S3). Acute stimulation of WNK1 activity by
IGF1 potentiates PLC-b signaling byw2-fold (Figures 7A and
7B). WNK1 thus controls a major mode of desensitization of
Gq signaling in addition to modulating acute responses. PIP2
itself is a signaling molecule that regulates many plasma
membrane targets [36]. Increasing PIP2 synthesis by WNK1
is thus an important mechanism for increasing cellular DAG
and IP3 concentrations without causing untoward effects of
decreases in membrane PIP2 on other targets.
PLC-b enzymes function as coincidence detectors that
synergistically integrate multiple upstream inputs including
Gaq, Gbg, Ca
2+, and Rac [37, 38, 39]. These mechanisms of
synergism are results of combined superadditive stimulation
of the catalytic activity of PLC-b. In contrast, synergism
between WNK1 and Gaq depends on the ability of WNK1 to
enhance substrate supply for PLC-b. This system is analogous
to the interaction between PLCs and inositol phosphate
kinases in which PLC provides the IP3 starting material that
the cell-type-specific kinases then phosphorylate to the
appropriate inositol polyphosphates [40].
The interactive control of PLC-b by WNK and Gq may have
important implications in the pathogenesis of hypertension
in patients with PHA2 that is caused by mutations of WNK1
that increase WNK1 expression [2]. Gq/11-mediated PLC-b
signaling plays a central role in the regulation of vasculartone by virtually all vasoactive hormones
[41], and potentiation of PLC-b signaling by
WNK1 would promote vasoconstriction and
cause hypertension. The role of WNK1 in the
regulation of vascular tone is supported by
the report that mice with heterozygous in-
activation of Wnk1 display reduced bloodpressure without renal Na+ wasting and hypovolemia [42].
Finally, the similarity between the phenotypes of WNK1-
knockout and Gaq/Ga11-knockout mice (both lethal at embry-
onic day w10.5, with cardiac defects) supports the idea that
interaction between the WNK1 and Gaq/11 pathways is impor-
tant for embryonic development [10, 26].
In conclusion, WNK1 potentiates Gq-PLC-b signaling by
stimulating the activity of PI4KIIIa to increase synthesis of
PIP2. Phosphorylation of WNK1 by Akt kinase increases its
activity in this pathway and allows tyrosine kinase receptors
or other activators of the Akt kinase cascade to regulate G
protein-mediated PLC-b signaling. The extent and physiolog-
ical role of WNK1 in the regulation of PLC-b signaling will
probably differ among specialized cells. Our understanding
of these interactions should expand as we learn more ways
in which WNK1 activity is regulated.
Experimental Procedures
Detailed experimental procedures are in the Supplemental Information.
HEK293 and HeLa cells and mouse embryonic fibroblasts were cultured
and cotransfected with complementary DNAs (cDNAs) for TRPC6-Flag
with or without human M3 muscarinic receptor [43]. Ruptured whole-cell,
cell-attached, and inside-out excised patch-clamp recording were per-
formed as described [9, 43]. Intracellular Ca2+ transients were examined
using ratiometric fluorescent Ca2+ images of fura-2-loaded cells. PIP2 and
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1986IP3 were localized according to fluorescence of a GFP-tagged PLC-d1-PH
domain by confocal microscopy [34]. PLC activity was measured by moni-
toring hydrolysis of [3H]PIP2 on large unilamellar phospholipid vesicles
[22, 37]. PI4KIIIa activity from HeLa cells was measured by phosphorylation
of phosphatidylinositol (PI) in PI/Triton X-100-mixed micelles [44].
Supplemental Information
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.cub.2011.11.002.
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